# Draft Guidances Relating to the Development of Biosimilar Products; Public Hearing; Request for Comments; Correction
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice of public hearing; request for comments; correction.
**SUMMARY:**
The Food and Drug Administration (FDA) is correcting a notice that appeared in the *Federal Register* of March 2, 2012 (77 FR 12853). The document announced a public hearing entitled “Draft Guidances Related to the Development of Biosimilar Products; Public Hearing; Request for Comments” to obtain input on recently issued draft guidances relating to the development of biosimilar products. The document published with an incorrect date for submission of electronic and written comments. This document corrects that error.
**FOR FURTHER INFORMATION CONTACT:**
Sandra J. Benton, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6340, Silver Spring, MD 20993-0002, 301-796-1042, Fax: 301-847-3529, email: *[email protected]* .
**SUPPLEMENTARY INFORMATION:**
In FR Doc. 2012-5070, appearing on page 12853, in the *Federal Register* of Friday, March 2, 2012, the following correction is made:
On page 12853, in the second column, in the *DATES* section, the last sentence is corrected to read: “Electronic or written comments will be accepted after the public hearing until May 25, 2012.”
Dated: March 26, 2012.
Leslie Kux,
Assistant Commissioner for Policy.